Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03499639
Other study ID # IRB 17100240
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date May 1, 2018
Est. completion date September 30, 2018

Study information

Verified date January 2020
Source Assiut University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Management of patients with hepatitis C virus (HCV) related liver disease with concomitant co-morbidity was challenging, especially in the period before the era of new direct-acting antiviral (DAA) agents. With the introduction of DAAs protocols, the therapeutic options were expanded to endorse many patients that were previously assigned as difficult-to-treat population. Different situations were encountered with co-infection with HCV such as chronic kidney disease (CKD) with its spectrum from mild forms to the end-stage kidney disease (ESKD), patients on hemodialysis (HD), and in post-renal transplant settings. Till now, pooled data about the safety and efficacy of different DAAs regimens in different renal situations are still under evaluation, especially in Egypt, where HCV genotype 4 the most dominating genotype. In Egypt, there were two adopted protocols for patients with HCV and CKD; the sofosbuvir-based combinations and the ombitasvir, paritaprevir, and ritonavir plus ribavirin-based combination. Sofosbuvir was proved to be contraindicated in patients with end-stage renal diseases as its elimination based mainly on renal route that may affect its bioavailability. On the other hand, ombitasvir, paritaprevir, and ritonavir plus ribavirin regimen was proved to be a well-tolerated protocol in non-cirrhotic patients with CKD.


Description:

Introduction Management of patients with hepatitis C virus (HCV) related liver disease with concomitant co-morbidity was challenging, especially in the period before the era of new direct-acting antiviral (DAA) agents. With the introduction of DAAs protocols, the therapeutic options were expanded to endorse many patients that were previously assigned as difficult-to-treat population [ ]. Different situations were encountered with co-infection with HCV such as chronic kidney disease (CKD) with its spectrum from mild forms to the end-stage kidney disease (ESKD), patients on hemodialysis (HD), and in post-renal transplant settings [ , ]. Till now, pooled data about the safety and efficacy of different DAAs regimens in different renal situations are still under evaluation [ ], especially in Egypt, where HCV genotype 4 the most dominating genotype [ ]. In Egypt, there were two adopted protocols for patients with HCV and CKD; the sofosbuvir-based combinations and the ombitasvir, paritaprevir, and ritonavir plus ribavirin-based combination [5, ]. Sofosbuvir was proved to be contraindicated in patients with end-stage renal diseases as its elimination based mainly on renal route that may affect its bioavailability [ ]. On the other hand, ombitasvir, paritaprevir, and ritonavir plus ribavirin regimen was proved to be a well-tolerated protocol in non-cirrhotic patients with CKD [6, ].

Aim Therefore, we herein, tried to evaluate a real-life practice to evaluate the efficacy and safety of ombitasvir, paritaprevir, and ritonavir plus ribavirin regimen in patients with ESKD, with or without hemodialysis in Egyptian based multicenter cohort.

Patients and Methods

Patients' recruitment:

Starting from July 2017, a prospective multicenter cohort study was designed to enroll all consecutive patients presented at the Viral Hepatitis Management Outpatient Clinic at Assiut University Hospital, South Valley University Hospital, Sohag University Hospital, Egypt, with proven CHC genotype 4 and concomitant ESKD with or without hemodialysis.

Enrolled patients were 18 years old or more, naive to HCV treatment, HCV genotype 4, and compensated liver disease. Patients with combined HCV/HBV co-infection, hepatocellular carcinoma (HCC), decompensated liver cirrhosis (Child-Pugh score above 6), and non-genotype 4 were excluded.

Study definitions

- ESKD was based on estimated glomerular filtration rate (eGFR) that calculated by the Cockroft-Gault equation [ , ].

- Two sets of patients: ESKD-group; eGFR less than between 59-30 ml/min without hemodialysis and HD-group; eGFR less than 30 ml/min with or without hemodialysis

- HCV Treatment Response: sustained virologic response was defined as HCV RNA under the detection limit at week 12 after the end of treatment (SVR12), non-responder was defined as a detectable viremia at week 12, and relapse was defined as re-appearance of HCV viremia during follow up after being undetectable at week 12 [ ].

Study methods and follow up protocol

- Liver disease-status was assessed before therapy by Child-Turcotte Pugh (CTP) score [ ] and liver stiffness score measurements by FibroscanĀ® (EchoSens, Paris, France) in kilopascals (kPa) according to the manufacturer's instructions (score less than 7.4 kPa equal to F0-F2, 9.5-12.4 kPa equal to F3, and 14.5 kPa or greater equal to F4 on METAVIR pathologic scoring system) [ , ].

- HCV genotype assessment by direct sequencing of the 50 untranslated region (50UTR), using RT-PCR-based assay (AmpliSens HCV-genotype-FRT PCR kit).

- HCV RNA was measured using the Roche COBAS Taq Man HCV assay version 2.0 (lower limit of detection 15 IU/mL).

- In all patients, hematologic (hemoglobin level) liver (CTP score parameters), renal (eGFR), and virologic (HCV-RNA viremia), and the co-medications such as immunosuppressive drugs (doses and levels), were evaluated at base-line (week0), at weeks 4, 12 during therapy, and week 24 after.

HCV Medications & protocols (Figure 1)[according to the National Committee for Control of Viral Hepatitis (NCCVH)]

- Patients with eGFR between 59-30ml/min: a co-formula of ombitasvir (OBV; 25mg)/ paritaprevir (PTV; 150mg)/ ritonavir (r; 100mg) (OBV/PTV/r) once-daily plus ribavirin (RIB) was given for 12 weeks. Dose adjustment of RIB was made as follow: If eGFR was 30-59 ml/min, an alternating dosing of 200 mg and 400 mg daily; if eGFR 15-30 ml/min, dosing was 200 mg once daily.

- Patients on hemodialysis: a co-formula of OBV/PTV/r (25/150/100mg) once-daily plus RIB 200 mg 3 times/week, only in the days that they have their hemodialysis settings, 4 hours before the hemodialysis setting for 12 weeks.

Study outcome measures & endpoints The primary endpoint was the achievement of SVR at week 12 (SVR12) post-treatment. The potential adverse events were evaluated in each visit for the development of adverse events or any significant interactions.

Statistical analysis and ethical considerations Frequencies, percentages, and means were used, as appropriate, for descriptive analysis. Chi Square test was used to compare parametric qualitative data, while Mann-Whitney test was used to compare non-parametric qualitative data and fisher exact test used to compare non-parametric qualitative data. Statistical analysis was conducted by SPSS (V.19, SPSS Inc.; Chicago, IL, USA). A p-value < 0.05 was considered significant. The study was approved by the local Ethical Committee.


Recruitment information / eligibility

Status Completed
Enrollment 110
Est. completion date September 30, 2018
Est. primary completion date August 1, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- patients were 18 years old or more,

- naive to HCV treatment,

- HCV genotype 4,

- compensated liver disease.

Exclusion Criteria:

- Patients with combined HCV/HBV co-infection

- hepatocellular carcinoma (HCC)

- decompensated liver cirrhosis (Child-Pugh score above 6)

- non-genotype 4

Study Design


Intervention

Drug:
Ombitasvir / Paritaprevir / Ritonavir /Ribavirin Oral Tablet
Patients with eGFR between 59-30ml/min: a co-formula of ombitasvir (OBV; 25mg)/ paritaprevir (PTV; 150mg)/ ritonavir (r; 100mg) (OBV/PTV/r) once-daily plus ribavirin (RIB) was given for 12 weeks. Dose adjustment of RIB was made as follow: If eGFR was 30-59 ml/min, an alternating dosing of 200 mg and 400 mg daily; if eGFR 15-30 ml/min, dosing was 200 mg once daily. Patients on hemodialysis: a co-formula of OBV/PTV/r (25/150/100mg) once-daily plus RIB 200 mg 3 times/week, only in the days that they have their hemodialysis settings, 4 hours before the hemodialysis setting for 12 weeks.

Locations

Country Name City State
Egypt Assiut University Hopsital Assiut

Sponsors (3)

Lead Sponsor Collaborator
Assiut University Sohag University, South Valley University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary The primary endpoint was the achievement of SVR at week 12 (SVR12) post-treatment. 6 months
Secondary The potential adverse events were evaluated in each visit for the development of adverse events or any significant interactions. 6 months
See also
  Status Clinical Trial Phase
Completed NCT04087213 - Study of HemoCareā„¢ Hemodialysis System for Home Nocturnal Dialysis in Patients With ESRD N/A
Completed NCT02207088 - Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease Phase 3
Not yet recruiting NCT03090828 - Economic Evaluation of an Education Platform for Patients With End-stage Renal Disease N/A
Completed NCT02237521 - The Effect of the Incretin Hormones on the Endocrine Pancreatic Function During Hyperglycemia in End-stage Renal Disease N/A
Withdrawn NCT01691196 - Inflammation in Peritoneal Dialysis Patients: Effect of Obesity
Completed NCT01394341 - Liraglutide Treatment to Patients With Severe Renal Insufficiency Phase 4
Active, not recruiting NCT00247507 - The Effects of Acetylcysteine on Alleviating Damage of Oxidative Stress in Hemodialysis Patients Phase 4
Completed NCT00307463 - Effects of Strict Volume Control in Hypertensive Hemodialysis Patients on Cardiac Structure and Chronic Inflammation Phase 4
Recruiting NCT00155363 - Effect of Different Hemodialysis Modality on Adiponectin,Vascular Function and Clinical Prognosis Phase 4
Completed NCT00234156 - The Effect of Fructose on Blood Fats in Dialysis Patients and Healthy Volunteers N/A
Completed NCT00586131 - Arterial pH and Total Body Nitrogen Balances in APD Phase 4
Active, not recruiting NCT05027074 - Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007) Phase 2
Recruiting NCT04575077 - The Role of Hepcidin as a Biomarker to Predict Successful Renal Transplantation
Enrolling by invitation NCT05001009 - Goals of Care Conversations Study N/A
Completed NCT01756508 - Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion Injury Phase 2
Recruiting NCT03862859 - The Danish Warfarin-Dialysis Study - Safety and Efficacy of Warfarin in Patients With Atrial Fibrillation on Dialysis Phase 4
Terminated NCT03661229 - Cardiovascular and Respiratory Assessment Using Biometric Signals in a Non-contact Monitoring Device N/A
Completed NCT03288922 - Protein-bound Toxin Removal Between Limited Blood Flow Super High-flux Online HDF and High-Efficiency Online HDF N/A
Completed NCT02360748 - A Plant Based High Protein Diet to Improve Nutritional Outcomes in Peritoneal Dialysis Patients N/A
Completed NCT02572882 - Gut Microbiome and p-Inulin in Hemodialysis N/A